查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1819916

2025-2033 年药物基因组学市场（按技术、应用、最终用户和地区）报告

Pharmacogenomics Market Report by Technology, Application, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3个工作天内

价格

2024 年全球药物基因体学市场规模达 86 亿美元。展望未来， IMARC Group预计到 2033 年市场规模将达到 170 亿美元，2025-2033 年期间的成长率 (CAGR) 为 7.55%。

药物基因体学是研究人类基因对特定药物反应的遗传变异的学科。它利用药理学和基因组学的原理，开发根据个体基因组成客製化的有效且安全的药物。它涉及多种技术，例如聚合酶炼式反应 (PCR)、微阵列、脱氧核糖核酸 (DNA) 定序、质谱和电泳。药物基因组学中进行的基因检测有助于确定对某些疾病的易感性以及新开发药物的疗效。药物基因组学也广泛应用于各种疾病的治疗，例如心血管疾病、阿兹海默症、癌症、人类免疫缺陷病毒和后天免疫缺乏症候群 (HIV/AIDS) 以及气喘。

药物基因组学市场趋势：

全球製药业的显着成长是市场前景乐观的关键因素之一。此外，对安全性更高的精准医疗的需求日益增长，也推动了市场的成长。随着慢性生活方式疾病的日益流行，副作用最小、疗效较佳的标靶药物疗法已被广泛应用。同时，药物基因组学也广泛应用于癌症治疗，并用于预测化疗和标靶免疫生物製剂的潜在药物反应、抗药性、疗效和毒性，这也促进了市场的成长。此外，各种技术进步，例如药物基因组学生物标誌标记解决方案的开发，也成为其他成长诱导因素。它们有助于最大限度地降低体内可避免的药物不良反应 (ADR) 的风险，并改善临床疗效。其他因素，包括广泛的研发活动以及医疗保健基础设施的显着改善，预计将推动市场成长。

本报告回答的关键问题

  • 药物基因组学市场有多大？药物基因组学市场未来前景如何？
  • 推动药物基因体学市场发展的关键因素有哪些？
  • 全球药物基因组学市场领先的公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球药物基因体学市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依技术

  • 聚合酶炼式反应
  • 微阵列
  • DNA定序
  • 质谱法
  • 电泳
  • 其他的

第七章：市场区隔：依应用

  • 肿瘤学
  • 传染病
  • 心血管疾病
  • 神经系统疾病
  • 精神病学
  • 疼痛管理
  • 其他的

第 8 章：市场区隔：依最终用户

  • 医院和诊所
  • 学术及研究机构

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 10 章：SWOT 分析

第 11 章：价值链分析

第 12 章：波特五力分析

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • AstraZeneca plc
    • Bayer AG
    • Becton Dickinson and Company
    • Bio-Rad Laboratories Inc.
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline plc
    • Illumina Inc.
    • Johnson & Johnson
    • Merck KGaA
    • Myriad Genetics Inc.
    • Qiagen NV
    • Thermo Fisher Scientific Inc
Product Code: SR112025A4396

The global pharmacogenomics market size reached USD 8.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 17.0 Billion by 2033, exhibiting a growth rate (CAGR) of 7.55% during 2025-2033.

Pharmacogenomics is the study of inherited variations in human genes in response to specific drugs. It utilizes the principles of pharmacology and genomics to develop effective and safe medications that are customized to the genetic makeup of an individual. It involves the use of various technologies, such as polymerase chain reaction (PCR), microarray, deoxyribonucleic acid (DNA) sequencing, mass spectrometry and electrophoresis. The genetic tests performed in pharmacogenomics aid in determining the susceptibility to certain diseases and efficacy of the newly developed drugs. Pharmacogenomics is also widely used in the treatment of various diseases, such as cardiovascular, Alzheimer's, cancer, human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS) and asthma.

Pharmacogenomics Market Trends:

Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing demand for precision medicines with enhanced drug safety is providing a thrust to the growth of the market. With the increasing prevalence of chronic lifestyle diseases, there is widespread adoption of targeted drug therapies with minimal side effects and improved efficacy. In line with this, pharmacogenomics is also extensively used for cancer treatments and anticipating the possible drug responses, resistance, efficacy and toxicity of the chemotherapeutic and targeted immune biologic agents, which is also contributing to the market growth. Additionally, various technological advancements, such as the development of pharmacogenomic biomarker labeling solutions, are acting as other growth-inducing factors. They aid in minimizing the risks of avoidable adverse drug reactions (ADRs) in the body and improve clinical outcomes. Other factors, including extensive research and development (R&D) activities, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.

Key Market Segmentation:

Breakup by Technology:

  • Polymerase Chain Reaction
  • Microarray
  • DNA Sequencing
  • Mass Spectrometry
  • Electrophoresis
  • Others

Breakup by Application:

  • Oncology
  • Infectious Diseases
  • Cardiovascular Diseases
  • Neurological Diseases
  • Psychiatry
  • Pain Management
  • Others

Breakup by End User:

  • Hospitals and Clinics
  • Academic and Research Institutes

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AstraZeneca plc, Bayer AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Illumina Inc., Johnson & Johnson, Merck KGaA, Myriad Genetics Inc., Qiagen N.V. and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

  • 1.How big is the pharmacogenomics market?
  • 2.What is the future outlook of pharmacogenomics market?
  • 3.What are the key factors driving the pharmacogenomics market?
  • 4.Which are the leading companies in the global pharmacogenomics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmacogenomics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Polymerase Chain Reaction
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Microarray
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 DNA Sequencing
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Mass Spectrometry
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Electrophoresis
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Infectious Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cardiovascular Diseases
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Neurological Diseases
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Psychiatry
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Pain Management
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Academic and Research Institutes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Becton Dickinson and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Bio-Rad Laboratories Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 F. Hoffmann-La Roche AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 SWOT Analysis
    • 14.3.7 GlaxoSmithKline plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Illumina Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Johnson & Johnson
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck KGaA
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Myriad Genetics Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Qiagen N.V.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Thermo Fisher Scientific Inc
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Pharmacogenomics Market: Major Drivers and Challenges
  • Figure 2: Global: Pharmacogenomics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Pharmacogenomics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Pharmacogenomics Market: Breakup by Technology (in %), 2024
  • Figure 5: Global: Pharmacogenomics Market: Breakup by Application (in %), 2024
  • Figure 6: Global: Pharmacogenomics Market: Breakup by End User (in %), 2024
  • Figure 7: Global: Pharmacogenomics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Pharmacogenomics (Polymerase Chain Reaction) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Pharmacogenomics (Polymerase Chain Reaction) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Pharmacogenomics (Microarray) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Pharmacogenomics (Microarray) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Pharmacogenomics (DNA Sequencing) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Pharmacogenomics (DNA Sequencing) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Pharmacogenomics (Mass Spectrometry) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Pharmacogenomics (Mass Spectrometry) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Pharmacogenomics (Electrophoresis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Pharmacogenomics (Electrophoresis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Pharmacogenomics (Other Technologies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Pharmacogenomics (Other Technologies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Pharmacogenomics (Oncology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Pharmacogenomics (Oncology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Pharmacogenomics (Infectious Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Pharmacogenomics (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Pharmacogenomics (Cardiovascular Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Pharmacogenomics (Cardiovascular Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Pharmacogenomics (Neurological Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Pharmacogenomics (Neurological Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Pharmacogenomics (Psychiatry) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Pharmacogenomics (Psychiatry) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Pharmacogenomics (Pain Management) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Pharmacogenomics (Pain Management) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Pharmacogenomics (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Pharmacogenomics (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Pharmacogenomics (Hospitals and Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Pharmacogenomics (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Pharmacogenomics (Academic and Research Institutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Pharmacogenomics (Academic and Research Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: North America: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: North America: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: United States: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: United States: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Canada: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Canada: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Asia-Pacific: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Asia-Pacific: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: China: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: China: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Japan: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Japan: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: India: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: India: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: South Korea: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: South Korea: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Australia: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Australia: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Indonesia: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Indonesia: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Others: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Others: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Europe: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Europe: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Germany: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Germany: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: France: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: France: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: United Kingdom: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: United Kingdom: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Italy: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Italy: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Spain: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Spain: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Russia: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Russia: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Others: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Others: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Latin America: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Latin America: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Brazil: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Brazil: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Mexico: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Mexico: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Others: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Others: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Middle East and Africa: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Middle East and Africa: Pharmacogenomics Market: Breakup by Country (in %), 2024
  • Figure 86: Middle East and Africa: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Global: Pharmacogenomics Industry: SWOT Analysis
  • Figure 88: Global: Pharmacogenomics Industry: Value Chain Analysis
  • Figure 89: Global: Pharmacogenomics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pharmacogenomics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Pharmacogenomics Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 3: Global: Pharmacogenomics Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 4: Global: Pharmacogenomics Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Pharmacogenomics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Pharmacogenomics Market: Competitive Structure
  • Table 7: Global: Pharmacogenomics Market: Key Playe